131 related articles for article (PubMed ID: 25141954)
1. ITC commentary on the prediction of digoxin clinical drug-drug interactions from in vitro transporter assays.
Lee CA; Kalvass JC; Galetin A; Zamek-Gliszczynski MJ
Clin Pharmacol Ther; 2014 Sep; 96(3):298-301. PubMed ID: 25141954
[TBL] [Abstract][Full Text] [Related]
2. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Schaefer O
Drug Metab Dispos; 2014 Feb; 42(2):257-63. PubMed ID: 24212378
[TBL] [Abstract][Full Text] [Related]
3. Calibration of in vitro multidrug resistance protein 1 substrate and inhibition assays as a basis to support the prediction of clinically relevant interactions in vivo.
Poirier A; Cascais AC; Bader U; Portmann R; Brun ME; Walter I; Hillebrecht A; Ullah M; Funk C
Drug Metab Dispos; 2014 Sep; 42(9):1411-22. PubMed ID: 24939652
[TBL] [Abstract][Full Text] [Related]
4. Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.
Neuhoff S; Yeo KR; Barter Z; Jamei M; Turner DB; Rostami-Hodjegan A
J Pharm Sci; 2013 Sep; 102(9):3161-73. PubMed ID: 23686764
[TBL] [Abstract][Full Text] [Related]
5. Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies.
Cook JA; Feng B; Fenner KS; Kempshall S; Liu R; Rotter C; Smith DA; Troutman MD; Ullah M; Lee CA
Mol Pharm; 2010 Apr; 7(2):398-411. PubMed ID: 20025245
[TBL] [Abstract][Full Text] [Related]
6. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein.
Keogh JP; Kunta JR
Eur J Pharm Sci; 2006 Apr; 27(5):543-54. PubMed ID: 16406207
[TBL] [Abstract][Full Text] [Related]
7. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
[TBL] [Abstract][Full Text] [Related]
8. Characterization of digoxin uptake in sandwich-cultured human hepatocytes.
Kimoto E; Chupka J; Xiao Y; Bi YA; Duignan DB
Drug Metab Dispos; 2011 Jan; 39(1):47-53. PubMed ID: 20926619
[TBL] [Abstract][Full Text] [Related]
9. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.
Acharya P; O'Connor MP; Polli JW; Ayrton A; Ellens H; Bentz J
Drug Metab Dispos; 2008 Feb; 36(2):452-60. PubMed ID: 17967933
[TBL] [Abstract][Full Text] [Related]
10. Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux.
Neuhoff S; Yeo KR; Barter Z; Jamei M; Turner DB; Rostami-Hodjegan A
J Pharm Sci; 2013 Sep; 102(9):3145-60. PubMed ID: 23703021
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein mediated efflux in Caco-2 cell monolayers: the influence of herbals on digoxin transport.
Oga EF; Sekine S; Shitara Y; Horie T
J Ethnopharmacol; 2012 Dec; 144(3):612-7. PubMed ID: 23064285
[TBL] [Abstract][Full Text] [Related]
12. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of A Model-Based Approach for Estimating In Vitro P-Glycoprotein Inhibition Potency in a Transcellular Transport Assay.
Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Maeda K; Sugiyama Y
J Pharm Sci; 2016 Feb; 105(2):891-896. PubMed ID: 26869433
[TBL] [Abstract][Full Text] [Related]
14. Suitability of digoxin as a P-glycoprotein probe: implications of other transporters on sensitivity and specificity.
Nader AM; Foster DR
J Clin Pharmacol; 2014 Jan; 54(1):3-13. PubMed ID: 24166743
[TBL] [Abstract][Full Text] [Related]
15. Selection of an Optimal In Vitro Model to Assess P-gp Inhibition: Comparison of Vesicular and Bidirectional Transcellular Transport Inhibition Assays.
Yabut J; Houle R; Wang S; Liaw A; Katwaru R; Collier H; Hittle L; Chu X
Drug Metab Dispos; 2022 Jul; 50(7):909-922. PubMed ID: 35489778
[TBL] [Abstract][Full Text] [Related]
16. Caco-2 cell methodology and inhibition of the P-glycoprotein transport of digoxin by Aloe vera juice.
Djuv A; Nilsen OG
Phytother Res; 2008 Dec; 22(12):1623-8. PubMed ID: 19003953
[TBL] [Abstract][Full Text] [Related]
17. From bench to bedside: utilization of an in vitro model to predict potential drug-drug interactions in the kidney: the digoxin-mifepristone example.
Woodland C; Koren G; Ito S
J Clin Pharmacol; 2003 Jul; 43(7):743-50. PubMed ID: 12856388
[TBL] [Abstract][Full Text] [Related]
18. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug.
Fenner KS; Troutman MD; Kempshall S; Cook JA; Ware JA; Smith DA; Lee CA
Clin Pharmacol Ther; 2009 Feb; 85(2):173-81. PubMed ID: 18987624
[TBL] [Abstract][Full Text] [Related]
19. Unravelling the complex drug-drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein.
Ledwitch KV; Barnes RW; Roberts AG
Biosci Rep; 2016 Jan; 36(2):. PubMed ID: 26823559
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments].
Fromm MF; Kim RB; Stein CM; Wilkinson GR; Roden DM
Circulation; 1999 Feb; 99(4):552-7. PubMed ID: 9927403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]